1	Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without
2	adjustment for self-reported exposure risk
3	
4	Nicholas Brousseau ^{1,2,3*} , Sara Carazo ^{1,3} , Yossi Febriani ² , Lauriane Padet ¹ , Sandrine Hegg-Deloye ² ,
5	Geneviève Cadieux ^{4,5} , Geneviève Bergeron ⁴ , Judith Fafard ⁶ , Hugues Charest ^{6,7} , Gilles Lambert ⁴ , Denis
6	Talbot ³ , Jean Longtin ² , Alexandre Dumont-Blais ⁸ , Steve Bastien ⁸ , Virginie Dalpé ¹ , Pierre-Henri Minot ¹ ,
7	Gaston De Serres ^{1,2} , Danuta M. Skowronski ^{9,10} .
8	1 Biological Risks Department, Institut national de santé publique du Québec, Quebec, QC,
9	Canada
10	2 Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec,
11	QC, Canada
12	3 Social and Preventive Medicine Department, Faculty of Medicine, Laval University, Quebec,
13	QC, Canada
14	4 Direction régionale de santé publique de Montréal, Montreal, QC, Canada
15	5 Department of Epidemiology, Biostatistics and Occupational Health, McGill University,
16	Montréal, QC, Canada
17	6 Laboratoire de santé publique du Québec, Institut national de santé publique du Québec,
18	Québec, QC, Canada
19	7 Faculty of Medicine, University of Montreal, Montreal, QC, Canada
20	8 RÉZO Community Organization, Montreal, QC Canada
21	9 Immunization Programs and Vaccine Preventable Diseases Service, BC Centre for Disease
22	Control, Vancouver, British Columbia, Canada
23	10 School of Population and Public Health, University of British Columbia, Vancouver, British
24	Columbia, Canada
25	
26	Keywords
27	Epidemiology; immunization; monkeypox; mpox; vaccine effectiveness.
28	
29	Running title
30	MVA-BN effectiveness against mpox
31	
32	Contact information

- 33 * Corresponding author:
- 34 Nicholas Brousseau, MD, MSc, FRCP(C), Biological Risks Department, Institut national de santé publique
- 35 du Québec, 945 avenue Wolfe, Quebec, QC, G1V 5B3, Canada
- 36 <u>nicholas.brousseau@inspq.qc.ca</u>

37

38 **40-word summary of the article's main point**

- 39 When adjusting for differential exposure risk, one vaccine dose reduced the mpox risk by about two-
- 40 thirds using self-reported risk factors, but by only one-third using surrogate indicators available within
- 41 administrative databases. Inadequate adjustment for exposure risk under-estimates MVA-BN vaccine
- 42 effectiveness.
- 43
- 44 Number of words
- 45 2992 words
- 46
- 47 Number of words (abstract)
- 48 250 words
- 49

50 Abbreviations

- 51 All-Admin, participants meeting eligibility criteria and using administrative data only; CI, confidence
- 52 interval; gbMSM, gay, bisexual, and other men who have sex with men; GBTQ, gay, bisexual, trans,
- 53 queer; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; NAT, nucleic
- acid test; PNA, prefers not to answer; PrEP, pre-exposure prophylaxis; QPHL, Quebec Public Health
- 55 Laboratory; STI, sexually transmitted infection; Sub-Quest; subset of All-Admin participants who
- 56 completed the questionnaire; VE, vaccine effectiveness.
- 57

58 Abstract

59

60 Introduction

61 During the 2022 mpox outbreak, the province of Quebec, Canada prioritized first doses for pre-exposure

62 vaccination of people at high mpox risk, delaying second doses due to limited supply. We estimated single-

63 dose mpox vaccine effectiveness (VE) adjusting for virus exposure risk based only on surrogate indicators

available within administrative databases (e.g. clinical record of sexually transmitted infections), or
 supplemented by self-reported risk factor information (e.g. sexual contacts).

66

67 Methods

68 We conducted a test-negative case-control study between June 19 and September 24, 2022.

- 69 Information from administrative databases was supplemented by a questionnaire collecting self-
- 70 reported risk factors specific to the three-week period before testing. Two study populations were
- assessed: all within the administrative databases (All-Admin) and the subset completing the
- 72 questionnaire (Sub-Quest). Logistic regression models were adjusted for age, calendar-time and
- raise exposure-risk, the latter based on administrative indicators only (All-Admin and Sub-Quest populations)
- or supplemented by questionnaire information (Sub-Quest population).
- 75

76 Results

- 77 There were 532 All-Admin participants, of which 199 (37%) belonged to Sub-Quest. With exposure-risk
- adjustment based only on administrative indicators, single-dose mpox VE among All-Admin and Sub-
- 79 Quest populations was similar at 35% (95%CI:-2-59) and 30% (95%CI:-38-64), respectively. With
- adjustment supplemented by questionnaire information, Sub-Quest VE increased to 65% (95%CI:1-87).
- 81 Protection against severe outcomes was higher (VE=82%; 95%CI:-50-98) but with overlapping
- 82 confidence intervals.
- 83

84 Conclusions

- 85 One vaccine dose reduced mpox risk by about two-thirds when adjustment incorporated self-reported
- risk factors, but by only one-third when adjustment relied solely upon administrative indicators.
- 87 Inadequate adjustment for exposure risk may substantially under-estimate mpox VE.

89

90 Introduction

91

92 In May 2022, an mpox (formerly known as monkeypox) outbreak started in several non-endemic countries 93 prompting the World Health Organization (WHO) to declare a public health emergency of international 94 concern on July 23, 2022[1]. In the city of Montréal (Province of Qubec, Canada) the first mpox cases were 95 laboratory-confirmed on May 20, 2022. As of June 1, 2023, 79% of the 529 cases reported in Quebec were among Montreal residents. Transmission mostly occurred among communities of gay, bisexual, trans, 96 queer (GBTQ) men and other men who have sex with men (gbMSM). Outbreak control primarily relied on 97 98 surveillance, case and contact management, and pre-exposure vaccination with the Modified Vaccinia 99 Ankara—Bavarian Nordic [MVA-BN] vaccine (Imvamune [Canada], Jynneos [USA], Imvanex [Europe]).

100

101 MVA-BN is a third-generation non-replicating vaccine, approved by Health Canada in 2020 to prevent 102 orthopoxvirus infections[2]. Post-exposure MVA-BN vaccination began in Quebec on May 30, 2022 and on 103 June 3, 2022, Quebec became one of the first jurisdictions to offer pre-exposure vaccination[3,4], with 104 gradual roll-out first targeting gbMSM at high-risk of exposure, and progressively extended to sex workers 105 and people working in sex-on-premise venues. The standard MVA-BN vaccination regimen consists of two 106 subcutaneous doses, 28 days apart. Due to limited supply, providing the first MVA-BN dose to as many as 107 possible, including to foreign visitors, was prioritized in Quebec[5] and Canada[6], thereby delaying 108 second doses. In Quebec, the second dose was initially restricted to immunocompromised persons and 109 became offered widely as of October 6, 2022. As of June 1, 2023, a total of 31,000 first doses and 13,000 110 second doses had been administered in Quebec.

111

The efficacy of MVA-BN pre-exposure vaccination against mpox has never been demonstrated in clinical trials. Several observational studies have attempted to evaluate single-dose vaccine effectiveness (VE) against mpox disease with widely varying estimates ranging between 36%[7] and 86%[8]. Most studies, however, have relied upon administrative databases lacking specific details on exposure risk, and using surrogate indicators as proxy for mpox exposure risk. With limited vaccine doses targeted toward highrisk individuals, differential exposure risk between vaccinated and unvaccinated persons may pose a particular threat to valid VE estimation.

In this test-negative case-control study, we estimated the effectiveness of subcutaneous single-dose MVA-BN vaccination against symptomatic mpox infection, including moderate-to-severe disease. We compared mpox VE estimates with adjustment for exposure risk based solely on surrogate indicators of risk, as typically available within administrative databases, or supplemented by self-reported risk factor information specific to the three-week period before mpox testing.

- 125
- 126 Methods
- 127
- 128 Design

We conducted a test-negative case-control study using skin or mucous membrane specimens that were
 tested for *orthopoxvirus* infections by nucleic acid test (NAT) at the Quebec Public Health Laboratory

131 (QPHL). Cases were test-positive. Controls were individuals with only negative NAT tests. Among those

132 with multiple test-negative specimens, only the first-ever specimen for orthopoxvirus testing, collected

- 133 during the study period, was used.
- 134

135 Data sources

136 Administrative data

137 We obtained information on cases and controls from several administrative and surveillance databases.

138 The QPHL data included all *orthopoxviruses* NAT test results, date and place of specimen collection, age,

139 sex and human immunodeficiency virus (HIV) status (any past positive test result). Mpox vaccination

140 data were retrieved from the Provincial Immunization Registry, a populational registry where all

immunizations have to be recorded by law[9]. Information on sexually transmitted infection (STI) testing

142 (chlamydia, gonorrhea and syphilis) was retrieved from the *Dossier Santé Québec* database containing

individual clinical information, while positive STI tests were identified within the provincial notifiabledisease registry.

145

For cases, mpox clinical data (hospitalization, complications) were also obtained from the provincial
 notifiable disease registry. Tecovirimat treatment information was retrieved from the only designated
 pharmacy allowed to distribute the medication in the province (*Centre hospitalier universitaire de Montréal*).

- 150
- 151 <u>Questionnaire data</u>

152 We supplemented administrative data with self-reported sociodemographic and exposure data 153 collected from both cases and controls using a standardized questionnaire available in French, English 154 and Spanish. The questionnaire was adapted from tools used for public health epidemiological 155 investigations (Supplementary Methods). Between January 10 and March 27, 2023, cases and controls 156 were invited by email to complete the questionnaire on-line, with three reminders. Trained interviewers 157 attempted to contact non-responders and those without an e-mail address by phone, with three 158 reminders. Participation was actively promoted by the main health and STI prevention organization serving gbMSM communities in Montreal (RÉZO)[10], and \$30 financial compensation was given to 159

160 161

162 The questionnaire collected vaccination status and additional demographic and clinical information such

as ethnocultural background, immunosuppression, and HIV pre-exposure prophylaxis (PrEP). When

164 MVA-BN vaccination was not in the Immunization Registry but reported by participants with a specific

date, the participant was considered vaccinated. The questionnaire specifically queried details related to

166 mpox exposure risk during the 3 weeks before specimen collection including contact with a person with

167 mpox symptoms, number of sexual partners, drug use before or during sexual activity, sex involving > 2

168 people, attending sex-on-premise venues, and skin-to-skin contacts during a festive event.

169

170 Study population

participants.

The chosen study period spanned June 19 to September 24, 2022 (epidemiological weeks 26-38), taking
into account vaccine roll-out, a 14-day lag to mount effective single-dose immunity, and epidemic

evolution with cases peaking during June and July, and subsiding by mid-September 2022 (Figure 1).

174

Eligible specimens were restricted to those collected in Montreal where most cases occurred. Since most cases were men (according to health administrative databases), we excluded women. We also excluded individuals aged <18 years, those who tested positive before the study period, those whose only specimens were blood, serum or cerebrospinal fluid samples (not indicative of a skin or mucous membrane lesion), asymptomatic individuals, and persons residing outside of the province.

181 Two study populations were analyzed: (1) all participants meeting eligibility criteria and using

administrative data only (All-Admin); and (2) the subset of All-Admin participants who completed the

183 questionnaire (Sub-Quest).

184

185 Vaccination status

186 Vaccinated status was defined by receipt of a single dose of MVA-BN vaccine ≥14 days before specimen

187 collection. Those who had not received any MVA-BN vaccine dose before specimen collection were

188 considered unvaccinated. We excluded individuals who had received one MVA-BN dose <14 days or two

189 doses at any time before specimen collection.

190

191 Outcomes

192 Single-dose VE was primarily assessed against any laboratory-confirmed symptomatic infection, among

193 the All-Admin population and the Sub-Quest population separately. We also estimated VE against

194 moderate-to-severe disease defined by mpox disease-related hospitalization, having had a complication

195 or having received tecovirimat treatment. VE against moderate-to-severe disease could only be

undertaken using the All-Admin population owing to sample size considerations. The same control

197 group of any symptomatic but test-negative individuals was used in assessing VE for both clinical

198 outcomes.

199

200 Statistical analysis

201 Logistic regression models compared the adjusted odds of being a case versus a control by vaccine

status. VE was derived as (1 – odds ratio [OR_{adjusted}]) x 100. Analysis was performed using SAS (version

203 9.4).

204

For the All-Admin population, we adjusted models for the following variables available from linked
administrative databases: age group, calendar time, surrogate indicator of exposure risk ≤6 months
before the mpox test (no test for STI, only negative STI test results, ≥ 1 positive STI test results), and HIV
status (see Figure 3 for categories used).

209

For the Sub-Quest population, we compared VE based on two adjustment approaches: (1) adjusting as per above for variables available in administrative databases and (2) adjusting for variables available in administrative databases and also for information additionally available from the questionnaire: ethnocultural background, immunosuppression, HIV status/PrEP use, contact with a person who has mpox symptoms, number of sexual partners, drug use before or during sexual activity, sex involving > 2 people, attending sex-on-premise venues, skin-to-skin contacts during a festive event (see Figure 3 for

- 216 categories used). We defaulted to the guestionnaire responses for HIV status where discordant from
- administrative databases. There were no missing data for any variable included in the model.
- 218
- 219 To assess possible recall bias, we compared the number of sexual partners from the notifiable disease
- 220 registry recorded during public health investigation of reported cases (Summer 2022) versus
- 221 questionnaire capture (Winter 2023). We also undertook four additional sensitivity analyses of VE within
- the Sub-Quest population, including: (1) extension of the study period to include epidemiological weeks
- 223 22-24 and 39-44; (2) vaccination defined as \geq 21-days before specimen collection; (3) restriction to
- younger adults 18-49 years old; and (4) restriction to participants with self-reported PrEP use or HIV
- 225 diagnosis.
- 226

227 Ethics

- In the context of a public health emergency, this work was conducted under the legal mandate provided
- by the Quebec Public Health Act which allowed access to relevant administrative data[9] and was also
- approved by the *CHU de Québec-Université Laval* ethics committee.
- 231
- 232 Results
- 233

234 Study sample

- From June 19 to September 24 2022, there were 1025 individuals with a specimen submitted from
- 236 Montreal for mpox NAT analysis (277 cases; 748 controls) (Figure 2). Among these, 448 (44%) were
- excluded with main reasons being: asymptomatic and tested for a research project (348/448; 78%), and
- woman (81/448; 18%). After applying all exclusion criteria, 532 individuals (231 cases; 301 controls)
- 239 were included in the All-Admin analysis. The Sub-Quest subset who answered the questionnaire
- 240 included 199 (37%) participants (91 cases; 108 controls).
- 241

242 Case and control description

- Among the 532 All-Admin participants, half (116/231; 50%) NAT-positive cases were reported before
- 244 mid-July whereas most (162/301; 54%) NAT-negative controls were reported later in August and
- 245 September (Table 1). Slightly fewer cases than controls were vaccinated (26% vs. 34%, respectively).
- Few cases or controls were ≥50 years old (16% vs 22%). More cases than controls were HIV-positive
- 247 (22% vs. 14%) or had a positive STI test in the 6 months before mpox testing (26% vs. 10%).

2	л	0
	д	×

248	
249	Results based on administrative data were similar between the All-admin and Sub-Quest participants
250	(Table 1). By questionnaire, cases reported greater mpox exposure risk than controls during the 3 weeks
251	before specimen collection including ≥5 non-regular sexual partners (19% vs. 9%, respectively) and sex
252	involving > 2 people (32% vs. 23%). Nearly all cases (88/91; 97%) but fewer controls (93/108; 86%) had
253	at least one self-reported mpox exposure risk factor during the 3 weeks before testing. More cases were
254	HIV-negative but taking PrEP (47%) compared to controls (33%). Our questionnaire appeared slightly
255	more sensitive to identify HIV-positive individuals than administrative databases, as 18% of Sub-Quest
256	participants self-reported an HIV infection, but 14% of Sub-Quest participants had HIV according to
257	administrative (QPHL) data.
258	
259	In the questionnaire (completed on average 26 weeks post-diagnosis), 10/91 (10%) Sub-Quest cases
260	reported no sexual partners in the 3 weeks before specimen collection. In contrast, the notifiable
261	disease registry (data collected on average two weeks post-diagnosis) indicated that all 91 Sub-Quest
262	cases had reported sexual contact(s) during that period. There was otherwise good concordance
263	between these two data sources with respect to the number of sexual partners reported
264	(Supplementary Table 1).
265	
266	Single-dose MVA-BN vaccine effectiveness
267	Single-dose MVA-BN VE estimates against symptomatic infection among All-Admin and Sub-Quest
268	populations were 35% (95%CI: -2-59) and 30% (95%CI: -38-64), respectively, with adjustment for age,
269	calendar time and exposure risk based only upon administrative indicators (Figure 3, Supplementary
270	Table 2).
271	
272	Single-dose MVA-BN VE within the Sub-Quest population increased to 65% (95%CI:1-87) when adjusting
273	for age, calendar time and exposure risk with the latter further supplemented by questionnaire
274	information (Figure 3, Supplementary Table 2). The most influential questionnaire variable was HIV
275	PrEP use, with Sub-Quest VE of 50% (95%CI:-8-77) when only that questionnaire variable supplemented
276	age, calendar time and administrative indicators of exposure risk. However, other questionnaire
277	

277 covariates (without adjusting for HIV PreP) were also influential with VE of 45% (95%CI:-37-78) when 278 supplemental to age, calendar time and administrative indicators of exposure risk. 279

280 There were 12/208 (6%) moderate-to-severe cases during the study period within the All-Admin

281 population (of whom just 3 responded to the study questionnaire). Of these 12, three were hospitalized,

six (two also hospitalized) experienced complications, and five received tecovirimat treatment (one also

hospitalized). Only 1/12 moderate-to-severe cases (8%) had received MVA-BN vaccine compared with

284 101/287 controls (35%) suggesting higher VE against moderate-to-severe disease (82%; 95%CI: -39, 98)

- 285 (Figure 3, Supplementary Table 2).
- 286

287 Sensitivity analyses

288 Sensitivity analyses were performed on the Sub-Quest population, inclusive of questionnaire covariates.

289 When compared with the primary analysis (VE=65%; 95%CI:1-87), VE point estimates were slightly

lower, between 50-63%, when extending the study period earlier from May 29 or later to November 5,

291 based on vaccination ≥21 days before specimen collection or when restricting to people with an HIV

diagnosis or taking PrEP. VE was higher at 75% (95%CI:23-92) with restriction to adults 18-49 years

- 293 (Table 2).
- 294

295 Discussion

296 One MVA-BN vaccine dose during an mpox outbreak affecting gbMSM communities in Montreal was 297 associated with about two-thirds reduction in the risk of symptomatic mpox infection when adjustment 298 for mpox exposure risk included self-reported risk factors. The estimated risk reduction was much lower 299 (roughly one-third) when adjustment used only surrogate indicators of exposure risk available in 300 administrative databases. In sensitivity analyses, VE point estimates ranged 50-75%, indicating a 2-4-fold 301 lower mpox risk among single-dose vaccinated compared to unvaccinated individuals. Recognizing the 302 limited sample size, our findings also suggest greater protection against moderate-to-severe disease 303 compared to milder disease with estimated VE of about 80% corresponding to 5-fold risk reduction. 304

Prior MVA-BN VE studies based upon other observational designs including case-control, case-coverage and cohort approaches have reported widely ranging single-dose VE against mpox, with estimates spanning 36%[7] to ≥78%[7,8,11,12]. These analyses, however, were limited by the use of aggregate data only[11] and/or failure to adequately adjust for confounders such as differential exposure risk by vaccine status[7,8] and/or calendar time[8,11,12]. In addition to exposure risk adjustment, calendartime adjustment is also important to consider in observational estimation of VE, as previously wellestablished for influenza and COVID-19. When the incidence of mpox decreases with time across the study period and vaccinated person-time accrues later than unvaccinated person-time, VE will be overestimated[13]. Other mpox VE investigations based on classical matched case-control designs included controls that may have not presented with mpox symptoms, with single-dose mpox VE estimates of 68%[14] and 75%[15]. These estimates are slightly higher than our own, which was bases instead on a test-negative design that simultaneously standardized for healthcare seeking and testing indication, in addition to controlling for exposure risk and calendar time.

318

319 The lower single-dose VE estimates previously reported by Deputy et al. [7] (36%) is similar to our single-320 dose VE estimate among our All-Admin (35%) and Sub-Quest (30%) participants before incorporating 321 self-reported risk factors into covariate adjustment within the Sub-Quest population. Of note, the 322 comparability between our All-Admin and Sub-Quest populations when adjusting for the same 323 covariates is partially reassuring against selection bias potentially influencing the subset completing the 324 study questionnaire. The Deputy et al. results were based on a large case-control study applied to a 325 nationwide electronic health record database, matching cases and controls ≥18 years with incident diagnosis of HIV infection or an order for PrEP based upon week of the index event. In our study, 326 327 additionally adjusting for HIV PrEP alone had the greatest impact on VE (50%), but adjustment for other 328 self-reported risk factors further increased our overall single-dose VE estimate (65%). This insight was 329 achieved through actively contacting and querying cases and controls to document mpox exposure risk, 330 an added step not typically undertaken for controls. When we restricted our Sub-Quest population to 331 people taking PrEP or with an HIV diagnosis, our single-dose VE estimate (50%) was still higher, but 332 closer to that of Deputy et al.[7] That further stratification, however, was accompanied by reduced 333 sample size and wide confidence intervals. More research is needed to determine if restricting to people 334 taking HIV PrEP or adjusting for this variable as a surrogate indicator within administrative databases 335 could support valid VE estimation if/when self-reported mpox exposure risk cannot otherwise be 336 adequately documented[16].

337

Our finding of higher single-dose VE against moderate-to-severe disease was based on a single
 hospitalized vaccinated case, lacking statistical power but nevertheless consistent with immunogenicity
 studies. While two MVA-BN doses in non-primed individuals induced low levels of poorly neutralizing
 antibody[17], a single dose induced robust T-cell responses[18,19], with the latter more strongly
 correlated with protection against severe outcomes in general (e.g. against COVID-19 disease[20]).
 Other indirect evidence includes a cases series of mpox cases (without controls) in the United States by

Farrar et al.[21] that could not derive VE estimates, but found a lower proportion of 1-dose vaccinated (2.1%) versus unvaccinated (7.5%) cases that were hospitalized. While severe mpox fortunately remains infrequent, more definitive VE evaluation against that outcome will require much larger sample size.

348 This study has several limitations. The main limitation was the small sample size attributable to the 349 contained outbreak and participation rate to the guestionnaire which limited our capacity to undertake 350 further stratified analyses (e.g., to assess waning with time). Although we standardized for being symptomatic at the time of testing, controls may not have had symptoms of similar severity to 351 352 cases[22]. We can expect some level of recall bias with our questionnaire, as there was imperfect 353 agreement between information (e.g. sexual contacts) collected on average within two-weeks (case 354 investigation) versus 26 weeks (study questionnaire) after the diagnosis. Our questionnaire still enabled 355 us to adjust for self-reported mpox exposure risk, including variables less likely to be affected by recall 356 bias, such as HIV PrEP. We cannot rule out residual confounding due to unmeasured factors. Finally, we 357 provide evidence for single-dose protection delivered through subcutaneous injection but cannot 358 comment on other injection route or schedules (e.g. intradermal or two-dose). Other studies that have 359 evaluated two doses show improved VE[7,11,14,15], underscoring that a complete series remains 360 preferable when supply is sufficient.

361

In conclusion, during the 2022 mpox outbreak in Quebec, single-dose MVA-BN vaccine recipients were
at 2-4-fold lower risk of symptomatic mpox disease compared to unvaccinated individuals and vaccine
protection may be higher against severe outcomes. Incomplete adjustment for mpox exposure risk,
details of which are generally not available in administrative databases, may substantially underestimate mpox VE. In the context of MVA-BN scarcity and substantial single-dose protection, prioritizing
first doses and delaying second dose delivery can maximise benefit to the targeted population.

368

369 Funding

370

This work was supported by the Ministry of Health and Social Services. DT is supported by a research
career award from the Fonds de recherche du Québec – Santé.

- 374 Acknowledgements
- 375

376	We f	irst want to thank all participants who answered the questionnaire. We also thank RÉZO		
377	community, an organization for health and STIs prevention aimed at GBTQ men and other MSM, for			
378	their	help and expertise support throughout the project, and ensuring that the project would be well		
379	recei	ved by involved communities and answer their questions. We also thank Paul Le Guerrier and		
380	Robert Allard for their collaboration on the study design. We finally thank Eveline Toth, Hélène Venable			
381	and Annick Des Cormiers for their collaboration, and Christiane Audet, Charles Bellavance, Lucie Ferland			
382	Sophie Grenier, Gabrielle Guilbault, Sarah Shakibaian, and Maud Vallée for their help with data			
383	colle	ction and data extraction.		
384				
385	All au	thors participated in research design. N.B, S.C, L.P., S.H.G., J.F., and H.C. participated in the		
386	acqu	isition of the data. N.B, S.C, Y.F., S.H.G., D.T., G.D.S., and D.M.S. contributed to data analysis. N.B.		
387	wrot	e the first draft of the manuscript and all authors participated in the interpretation of data and		
388	revie	wed the article.		
389				
390	Pote	ntial conflicts of interest		
391				
392	None			
393				
394	Refe	rences		
395	1.	World Health Organization. WHO Director-General declares the ongoing monkeypox outbreak a		
396		Public Health Emergency of International Concern. 2022. Available at:		
397		https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-		
398		monkeypox-outbreak-a-public-health-event-of-international-concern. Accessed 06 July 2023.		
399	2.	Bavarian Nordic. IMVAMUNE [®] . 2020. Available at: https://pdf.hres.ca/dpd_pm/00058622.PDF.		
400		Accessed 06 July 2023.		
401	3.	Harrison LB, Bergeron G, Cadieux G, et al. Monkeypox in Montréal: Epidemiology, Phylogenomics,		
402		and Public Health Response to a Large North American Outbreak. Ann Intern Med 2023; 176:67–		
403		76.		
404	4.	Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. The		
405		Lancet Infectious Diseases 2022; 22:e349–e358.		

406 5. Comité sur l'immunisation du Québec. Vaccination contre la variole simienne, version 3.0. 2022.
407 Available at: https://www.inspq.qc.ca/publications/2867. Accessed 06 July 2023.

- 408 6. Government of Canada. NACI Rapid Response: Updated interim guidance on Imvamune in the
- 409 context of ongoing monkeypox outbreaks. 2022. Available at: https://www.canada.ca/en/public-
- 410 health/services/publications/vaccines-immunization/rapid-response-updated-interim-guidance-
- 411 imvamune-monkeypox-outbreaks.html. Accessed 06 July 2023.
- 412 7. Deputy NP, Deckert J, Chard AN, et al. Vaccine Effectiveness of JYNNEOS against Mpox Disease in
 413 the United States. N Engl J Med **2023**; :NEJMoa2215201.

8. Sagy Y, Zucker R, Hammerman A, et al. Real-world effectiveness of a single dose of mpox vaccine in
males. Nat Med **2023**; 29:748–752.

- 416 9. LegisQuébec. Public Health Act. 2023. Available at:
- 417 https://www.legisquebec.gouv.qc.ca/en/document/cs/S-2.2?&cible. Accessed 06 July 2023.
- 418 10. Institut national de santé publique du Québec. L'INSPQ mène une étude novatrice sur l'efficacité
- 419 du vaccin contre la variole simienne. 2023. Available at: https://www.inspq.qc.ca/nouvelles/l-
- 420 inspq-mene-etude-novatrice-sur-l-efficacite-du-vaccin-contre-variole-simienne. Accessed 06 July
 421 2023.
- 422 11. Payne AB, Ray LC, Cole MM, et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS
- 423 Vaccine Compared with Risk Among Unvaccinated Persons 43 U.S. Jurisdictions, July 31–

424 October 1, 2022. MMWR Morb Mortal Wkly Rep **2022**; 71:1560–1564.

- Bertran M, Andrews N, Davison C, et al. Effectiveness of one dose of MVA–BN smallpox vaccine
 against mpox in England using the case-coverage method: an observational study. The Lancet
 Infectious Diseases **2023**; :S1473309923000579.
- Boyer CB, Lipsitch M. Alternative analysis of mpox vaccine effectiveness data from Israel. MedRxiv
 https://doi.org/10.1101/2023.02.22.23286243 [Pre-print]. Jun 26, 2023 [cited 2023 July 09]. Available
 at: http://medrxiv.org/lookup/doi/10.1101/2023.02.22.23286243.
- 431 14. Rosenberg ES, Dorabawila V, Hart-Malloy R, et al. Effectiveness of JYNNEOS Vaccine Against
- 432 Diagnosed Mpox Infection New York, 2022. MMWR Morb Mortal Wkly Rep **2023**; 72:559–563.

- 433 15. Dalton AF, Diallo AO, Chard AN, et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing
- 434 Mpox: A Multijurisdictional Case-Control Study United States, August 19, 2022–March 31, 2023.
- 435 MMWR Morb Mortal Wkly Rep **2023**; 72:553–558.
- Fontán-Vela M, Hernando V, Olmedo C, et al. Reduction in the risk of mpox infection after MVA-BN
 vaccination in individuals on HIV pre-exposure prophylaxis: a Spanish cohort study. MedRxiv
 <u>https://doi.org/10.1101/2023.05.30.23290712</u> [Pre-print]. June 1, 2023 [cited 2023 July 09]. Available
 at: http://medrxiv.org/lookup/doi/10.1101/2023.05.30.23290712.
- 440 17. Zaeck LM, Lamers MM, Verstrepen BE, et al. Low levels of monkeypox virus-neutralizing antibodies
 441 after MVA-BN vaccination in healthy individuals. Nat Med **2023**; 29:270–278.
- 18. Cohn H, Bloom N, Cai G, et al. Mpox vaccine and infection-driven human immune signatures.
- 443 MedRxiv <u>https://doi.org/10.1101/2023.03.07.23286701</u> [Pre-print]. March 9, 2023 [cited July 2023 July
- 444 09]. Available at: http://medrxiv.org/lookup/doi/10.1101/2023.03.07.23286701. Accessed 06 July
 445 2023.
- Sammartino JC, Cassaniti I, Ferrari A, et al. Characterization of immune response against
 monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects. Journal of
 Medical Virology **2023**; 95:e28778.
- Fujii S, Yamasaki S, Iyoda T, Shimizu K. Association of cellular immunity with severity of COVID-19
 from the perspective of antigen-specific memory T cell responses and cross-reactivity. Inflamm
 Regener 2022; 42:50.
- 452 21. Farrar JL, Lewis NM, Houck K, et al. Demographic and Clinical Characteristics of Mpox in Persons
 453 Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons 29 U.S.
 454 Jurisdictions, May 22–September 3, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1610–1615.
- 22. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine
 Effectiveness: A Systematic Review of Methodology. Epidemiology 2020; 31:43–64.

458 Table 1. Characteristics of cases and controls among All-Admin and Sub-Quest populations, June 19 to

459 September 24, 2022

	All-Admin population (n=532)		Sub-Quest population (n=199)	
	Cases	Controls	Cases	Controls
	N (%)	N (%)	N (%)	N (%)
Overall	231	301	91	108
ADMINISTRATIVE DATABASE VARIABLES				
Age (years)				
18-29	50 (22)	90 (30)	21 (23)	28 (26)
30-49	143 (62)	146 (49)	57 (63)	55 (51)
50+	38 (16)	65 (22)	13 (14)	25 (23)
Epidemiological week of specimen collection				
25-28 (June 19 - July 16)	116 (50)	68 (23)	44 (48)	26 (24)
29-31 (July 17 - August 6)	53 (23)	71 (24)	21 (23)	26 (24)
32-34 (August 7 - August 27)	39 (17)	90 (30)	15 (16)	27 (25)
35-38 (August 28 - September 24)	23 (10)	72 (24)	11 (12)	29 (27)
Days between symptom onset and testing (median; IQR)	6 (4 - 9) ^a	NA	6 (4 - 8) ^a	NA
Vaccination status				
Unvaccinated	172 (74)	199 (66)	57 (66)	55 (51)
1 dose ≥14 days before testing	59 (26)	102 (34)	34 (37)	53 (49)
1 dose ≥21 days before testing	52 (23)	94 (31)	30 (33)	47 (47)
HIV infection (QPHL data)	51 (22)	42 (14)	15 (16)	13 (12)
Test done for chlamydia OR gonorrhea ^b	188 (81)	199 (66)	76 (84)	81 (75)
Test done for syphilis ^b	183 (79)	202 (67)	74 (81)	78 (72)
Positive test for chlamydia ^b	36 (16)	11 (4)	16 (18)	<5 (<5)
Positive test for gonorrhea ^b	39 (17)	20 (7)	17 (19)	11 (10)
Positive test for primary syphilis ^b	<5 (<5)	<5 (<5)	<5 (<5)	<5 (<5)
Overall: tests for STI ^b				
No test for STI	39 (17)	90 (30)	13 (14)	24 (22)
≥ 1 test for STI, no positive results	132 (57)	181 (60)	53 (58)	71 (66)
≥ 1 positive STI test results	60 (26)	30 (10)	25 (27)	13 (12)
QUESTIONNAIRE-ELICITED VARIABLES				
Gender				
Man	NA	NA	90 (99)	103 (95)
Other (woman, non-binary, PNA)	NA	NA	<5 (<5)	5 (5)
Ethnocultural background				
French Canadian	NA	NA	40 (44)	56 (52)
English Canadian	NA	NA	5 (5)	8 (7)
Other, do not know, PNA	NA	NA	46 (51)	44 (41)

Immunosuppression (excluding HIV)	NA	NA	7 (8)	<5 (<5)
HIV infection/PrEP use (study questionnaire)				
HIV infection	NA	NA	21 (23)	15 (14)
No HIV infection, PrEP use	NA	NA	43 (47)	36 (33)
No HIV infection, no PrEP	NA	NA	27 (30)	57 (53)
Skin-to-skin contact with person with mpox symptoms $^{ m c}$	NA	NA	39 (43)	14 (13)
Number of sexual partners ^c				
None	NA	NA	10 (11)	27 (25)
Only regular partner(s)	NA	NA	9 (10)	15 (14)
1-2 non-regular partners	NA	NA	28 (31)	27 (25)
3-4 non-regular partners	NA	NA	11 (12)	20 (19)
5 or more non-regular partners	NA	NA	17 (19)	10 (9)
Do not know, PNA	NA	NA	16 (18)	9 (8)
Use of drugs before/during sexual activity ^c	NA	NA	32 (35)	35 (32)
Sex involving > 2 people ^c	NA	NA	29 (32)	25 (23)
Attended sex-on-premise venues ^c	NA	NA	36 (40)	29 (27)
Skin-to-skin contact (with or without sex) during a festive event ^c	NA	NA	34 (37)	36 (33)
Overall: at least one exposure ^c	NA	NA	88 (97)	93 (86)

460 All-Admin population includes all participants with administrative data. Sub-Quest population includes

461 only the subset of All-Admin that completed the questionnaire. Cells sizes <5 hidden for privacy reasons.

462 Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; PNA,

463 prefers not to answer; PrEP, pre-exposure prophylaxis; QPHL, Quebec Public Health Laboratory; STI,

464 sexually transmitted infection.

^a Twenty-one missing data in the All-Admin population; four missing data in the Sub-Quest population.

466 $b \le 6$ months before mpox specimen collection.

467 ^c All self-reported exposures within 3 weeks of mpox specimen collection.

469 Table 2. Sensitivity analyses of single-dose MVA-BN vaccine effectiveness against symptomatic

470 mpox infection, Sub-Quest population inclusive of questionnaire covariates

471

	Cases	Controls	Adjusted ^a VE		
	N (%)	N (%)	(95% CI)		
Primary Sub-Quest analysis (June 19-September 24, 2	022: epidemiologica	al weeks 25-3	8)		
Unvaccinated	57 (63)	55 (51)	Ref.		
Single-dose vaccinated ≥14 days	34 (37)	52 (49)	65 (1, 87)		
Sensitivity analyses: extended study period (May 29-	September 24, 2022	: epi weeks 22	2-38) ^b		
Unvaccinated	83 (70)	71 (57)	Ref.		
Single-dose vaccinated ≥14 days	35 (30)	53 (43)	55 (-16, 83)		
Sensitivity analyses: extended study period (June 19-November 5, 2022: epidemiological weeks 25-44) ^c					
Unvaccinated	57 (62)	60 (49)	Ref.		
Single-dose vaccinated ≥14 days	35 (38)	63 (51)	63 (0, 87)		
Sensitivity analyses: extended study period (May 29-	November 5, 2022: e	epidemiologic	al weeks 22-44) ^d		
Unvaccinated	83 (70)	76 (55)	Ref.		
Single-dose vaccinated ≥14 days	36 (30)	63 (45)	54 (-18, 82)		
Sensitivity analyses: vaccinated ≥21 days before spec	cimen collection				
Unvaccinated	57 (66)	55 (54)	Ref.		
Single-dose vaccinated ≥21 days	30 (34)	47 (46)	52 (-45 <i>,</i> 84)		
Sensitivity analyses: Restricted to persons 18-49 year	rs old ^e				
Unvaccinated	51 (65)	44 (53)	Ref.		
Single-dose vaccinated ≥14 days	27 (35)	39 (47)	75 (23 <i>,</i> 92)		
Sensitivity analyses: Restricted to persons with HIV d	iagnosis or taking Pr	EP ^f			
Unvaccinated	35 (55)	17 (33)	Ref.		
Single-dose vaccinated ≥14 days	29 (42)	34 (67)	50 (-71, 85)		
Single-dose vaccinated ≥14 days	29 (42)	34 (67)	50 (-71, 8		

472 Abbreviations: HIV, human immunodeficiency virus; PNA, prefers not to answer; PrEP, pre-exposure

473 prophylaxis; Ref., Reference; STI, sexually transmitted infection; Sub-Quest, subset population

474 completing the questionnaire; VE, vaccine effectiveness.

^a Unless otherwise specified, Sub-Quest sensitivity models adjusted for age (18-29, 30-49, 50+ years),

476 calendar time (epidemiological weeks 25-28, 29-31, 32-34, and 35-38), STI tests and diagnosis (no test

477 for STI, only negative STI test results, ≥ 1 positive STI test results), ethnocultural background (French

478 Canadian, English Canadian, other/do not know/PNA), immunosuppression (yes/no), HIV status/PrEP

479 use according to questionnaire (HIV infection, no HIV infection without PrEP, no HIV infection with

480 PrEP), contact with a person who has mpox symptoms (yes, no, do not know/PNA), number of sexual

481 partners (0, only regular partners, 1-2 non-regular, 3-4 non-regular, 5+ non-regular, do not know/PNA),


482 drug use before or during sexual activity (yes, no, do not know/PNA), sex involving > 2 people (yes, no,

- 483 do not know/PNA), attending sex-on-premise venues (yes, no, do not know/PNA), skin-to-skin contacts
- 484 during a festive event (yes, no, do not know).
- 485 ^b Adjusted as per footnote ^a but with calendar time adjustment modified to additionally include
- 486 epidemiological weeks 22-24.
- 487 ^c Adjusted as per footnote ^a but with calendar time adjustment modified to additionally include
- 488 epidemiological weeks 39-44.
- 489 ^d Adjusted as per footnote ^a but with calendar time adjustment modified to additionally include
- 490 epidemiological weeks 22-24 and 39-44.
- ^e Adjusted as per footnote ^a but with age adjustment modified to 18-29 and 30-49 years. Categories "Do
- 492 not know" and "PNA" were grouped with the category "Yes" for the following variables: drug use before
- 493 or during sexual activity, sex involving > 2 people, attending sex-on-premises venues, skin-to-skin
- 494 contacts during a festive event.
- ^fAdjusted as per footnote ^a with the exception of immunosuppression. Categories for HIV status/PrEP
- 496 use: HIV infection, no HIV infection with PrEP. Categories "Do not know" and "PNA" were grouped with
- 497 the category "Yes" for the following variables: drug use before or during sexual activity, sex involving > 2
- 498 people, attending sex-on-premises venues, skin-to-skin contacts during a festive event.

500 Figure legends

501

502 Figure 1. Weekly distribution of study cases and vaccine administration in the province of Quebec,




503 May 22 to October 29, 2022.

504

All-Admin population includes all participants with administrative data. Sub-Quest population includes
only the subset of All-Admin that completed the questionnaire. The figure only includes positive NAT
tests for *Orthopoxviruses* at QPHL. QPHL started to test samples on May 26, 2022, but this included
individuals with specimen collection earlier than May 26 due to delay between specimen collection and
testing. Before May 26, tests were conducted at the National Microbiology Laboratory in Winnipeg,
Canada.
Abbreviations: NAT, nucleic acid amplification test; QPHL, Quebec Public Health Laboratory.

514 Figure 2. Flowchart of study population



515

516 All-Admin population includes all participants with administrative data (n=532). Sub-Quest population

517 includes only the subset of All-Admin that completed the questionnaire (n=199).


518 Abbreviations: CSF, cerebrospinal fluid; QPHL, Quebec Public Health Laboratory.

^a 1025 people with specimen collected in Montreal between June 19, 2022 and September 24, 2022.

521 Figure 3. Single-dose MVA-BN vaccine effectiveness against mpox infection by study population (All-

522 Admin or Sub-Quest), exposure risk adjustment (administrative indicators only or supplemented by

523 questionnaire) and clinical profile (any symptomatic or moderate-severe disease)



525 All-Admin population includes all participants with administrative data (n=532). Sub-Quest population includes only the subset

526 of All-Admin that completed the questionnaire (n=199). Moderate-to-severe disease defined by hospitalization because of

527 mpox disease or having had a complication or having received tecovirimat treatment. VE against moderate-to-severe disease

528 could only be undertaken using the All-Admin population owing to sample size considerations.

529 Abbreviations: HIV, human immunodeficiency virus; PNA, prefers not to answer, PrEP, pre-exposure prophylaxis; STI, sexually 530 transmitted infection.

*Adjusted for age (18-29, 30-49, 50+ years), calendar time (epidemiological weeks 25-28, 29-31, 32-34, and 35-38), STI tests

and diagnosis (no test for STI, only negative STI test results, ≥ 1 positive STI test results), HIV status according to QPHL data (yes,
 no).

534 **Adjusted for age (18-29, 30-49, 50+ years), calendar time (epidemiological weeks 25-28, 29-31, 32-34, and 35-38), STI tests

and diagnosis (no test for STI, only negative STI test results, ≥ 1 positive STI test results), ethnocultural background (French

536 Canadian, English Canadian, other/do not know/PNA), immunosuppression (yes/no), HIV status/PrEP use according to

537 questionnaire (HIV infection, no HIV infection without PrEP, no HIV infection with PrEP), contact with a person who has mpox

538 symptoms (yes, no, do not know/PNA), number of sexual partners (0, only regular partners, 1-2 non-regular, 3-4 non-regular, 5+

539 non-regular, do not know/PNA), drug use before or during sexual activity (yes, no, do not know/PNA), sex involving > 2 people

540 (yes, no, do not know/PNA), attending sex-on-premise venues (yes, no, do not know/PNA), skin-to-skin contacts during a festive

541 event (yes, no, do not know).